Fed. Circ. Upholds Ban On Teva's Generic Evista

By Allison Grande

Law360, New York (September 01, 2010, 7:05 PM ET) -- A federal appeals court has rejected Teva Pharmaceuticals USA Inc.'s bid to overturn a permanent injunction barring the generic-drug maker from launching a copy of Eli Lilly & Co.'s blockbuster osteoporosis drug Evista before March 2014.

A three-judge panel of the U.S. Court of Appeals for the Federal Circuit on Wednesday affirmed the lower court's September 2009 determination that four of Lilly's seven patents covering the oral administration of raloxifene hydrochloride to combat bone loss in post-menopausal women were valid and would be infringed by Teva's...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles